Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G; I-SPY 2 TRIAL Investigators; Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF 3rd, van 't Veer L. Wolf DM, et al. Among authors: esserman l. NPJ Breast Cancer. 2020 Oct 2;6:48. doi: 10.1038/s41523-020-00189-2. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 33083527 Free PMC article.
Breast cancer growth prevention by statins.
Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC. Campbell MJ, et al. Cancer Res. 2006 Sep 1;66(17):8707-14. doi: 10.1158/0008-5472.CAN-05-4061. Cancer Res. 2006. PMID: 16951186
Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Esserman LJ, et al. Breast Cancer Res Treat. 2011 Sep;129(2):607-16. doi: 10.1007/s10549-011-1564-5. Epub 2011 May 20. Breast Cancer Res Treat. 2011. PMID: 21597921 Free PMC article.
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ; I-SPY TRIAL Investigators. Lin C, et al. Among authors: esserman lj. Breast Cancer Res Treat. 2012 Apr;132(3):871-9. doi: 10.1007/s10549-011-1670-4. Epub 2011 Jul 28. Breast Cancer Res Treat. 2012. PMID: 21796368 Free PMC article.
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators. Esserman LJ, et al. Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25. Breast Cancer Res Treat. 2012. PMID: 22198468 Free PMC article.
463 results